We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $529M
1-Year Est. Return 337.4%
This Fund
S&P 500
This Quarter Est. Return
+27.32%
1 Year Est. Return
+337.4%
3 Year Est. Return
+710.06%
5 Year Est. Return
+1,177.67%
10 Year Est. Return
+20,064.24%
AUM
$529M
AUM Growth
+$94M
Cap. Flow
-$41.6M
Cap. Flow %
-7.87%
Top 10 Hldgs %
51.64%
Holding
54
New
12
Increased
7
Reduced
10
Closed
12

Top Buys

Rank Stock Value
1
ABVX
Abivax
ABVX
+$23.1M
2
VERA icon
Vera Therapeutics
VERA
+$15M
3
SGMT icon
Sagimet Biosciences
SGMT
+$13.8M
4
DFTX
Definium Therapeutics
DFTX
+$10.5M
5
IMMX icon
Immix Biopharma
IMMX
+$8.61M

Top Sells

Rank Stock Value
1
APGE
Apogee Therapeutics
APGE
+$31.5M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$16.2M
3
KALV
KalVista Pharmaceuticals
KALV
+$13.6M
4
IMVT icon
Immunovant
IMVT
+$13.6M
5
JBIO
Jade Biosciences
JBIO
+$13.6M

Sector Composition

Rank Sector Weight
1 Healthcare 78.18%
2 Miscellaneous 19.78%
3 Financials 2.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
CALL
Abivax
ABVX
$10.1B
$53.3M 10.07%
+400,000
New +$45.3M
VOR icon
2
Vor Biopharma
VOR
$1.32B
$31.3M 5.91%
1,700,000
-50,000
-3% -$757K
ABVX
3
Abivax
ABVX
$10.1B
$27.2M 5.15%
+204,314
New +$23.1M
IBRX icon
4
PUT
ImmunityBio
IBRX
$8.18B
$26.3M 4.97%
3,000,800
– –
VERA icon
5
Vera Therapeutics
VERA
$2.42B
$25.8M 4.87%
600,836
+401,488
+201% +$15M
ZURA icon
6
Zura Bio
ZURA
$516M
$24.9M 4.7%
4,215,930
– –
ALMS
7
Alumis Inc
ALMS
$1.28B
$24.1M 4.55%
856,061
– –
SLGL icon
8
Sol-Gel Technologies
SLGL
$219M
$20.3M 3.84%
274,363
– –
RARE icon
9
PUT
Ultragenyx Pharmaceutical
RARE
$1.42B
$20M 3.79%
+600,000
New +$14.9M
DFTX
10
Definium Therapeutics
DFTX
$5.07B
$20M 3.78%
+425,000
New +$10.5M
ANNX icon
11
Annexon
ANNX
$785M
$20M 3.78%
3,500,000
+1,000,000
+40% +$5.53M
ORKA
12
Oruka Therapeutics
ORKA
$6.07B
$17.4M 3.3%
183,330
– –
MLTX icon
13
MoonLake Immunotherapeutics
MLTX
$1.12B
$16.7M 3.15%
855,813
+355,813
+71% +$6.45M
SGMT icon
14
Sagimet Biosciences
SGMT
$687M
$15.7M 2.97%
+2,029,933
New +$13.8M
CTNM
15
Contineum Therapeutics
CTNM
$552M
$15.1M 2.85%
921,481
+121,283
+15% +$1.59M
IMMX icon
16
Immix Biopharma
IMMX
$909M
$13.2M 2.49%
1,277,642
+927,642
+265% +$8.61M
CLYM
17
Climb Bio
CLYM
$859M
$13M 2.46%
1,000,000
-334,130
-25% -$3.45M
AMLX icon
18
Amylyx Pharmaceuticals
AMLX
$3.58B
$12.6M 2.38%
700,000
-1,050,000
-60% -$16.2M
NKTR icon
19
Nektar Therapeutics
NKTR
$2.41B
$12.2M 2.31%
175,000
-141,453
-45% -$10.4M
NGNE icon
20
Neurogene
NGNE
$723M
$11.1M 2.09%
352,180
-147,820
-30% -$4.07M
LBRX
21
LB Pharmaceuticals
LBRX
$1.49B
$10.3M 1.95%
317,221
+17,221
+6% +$506K
IRD
22
Opus Genetics
IRD
$505M
$8.1M 1.53%
1,970,187
+1,645,847
+507% +$7.68M
EPRX
23
Eupraxia Pharmaceuticals
EPRX
$530M
$7.93M 1.5%
1,200,000
– –
DRUG
24
Bright Minds Biosciences
DRUG
$638M
$7.69M 1.45%
109,603
-110,397
-50% -$8.67M
IFRX icon
25
InflaRx
IFRX
$302M
$6.82M 1.29%
+3,046,557
New +$5.72M
1
2 3

Similar funds

KMWM
Keudell/Morrison Wealth Management Salem, Oregon $529M AUM
FFIC
First Fiduciary Investment Counsel Cleveland, Ohio $529M AUM 15.02% 1-Year Est. Return
TA
Teramo Advisors Naples, Florida $529M AUM 20.59% 1-Year Est. Return
JDLA
J. Derek Lewis & Associates Newport Beach, California $529M AUM
CCG
Clearlake Capital Group Santa Monica, California $529M AUM 50.26% 1-Year Est. Return
DAS
DMKC Advisory Services Des Moines, Iowa $530M AUM 22.27% 1-Year Est. Return
VAMG
Voisard Asset Management Group Grand Rapids, Michigan $529M AUM 21.43% 1-Year Est. Return
CWM
Compass Wealth Management Guilford, Connecticut $528M AUM 40.26% 1-Year Est. Return

Great Point Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Great Point Partners held 54 positions worth $529M, up 22% from $435M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Great Point Partners withdrew a net $41.6M in Q2 2026, closing 12 positions and reducing 10 holdings. Its most notable exit was Apogee Therapeutics, an estimated $31.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 94% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Great Point Partners opened a new position in Abivax worth $27.2M.

  • Great Point Partners's largest Q2 2026 buy was Abivax: 204,314 shares worth $27.2M.
  • Great Point Partners added most to Vera Therapeutics in Q2 2026, an estimated $15M increase.
  • Great Point Partners's biggest Q2 2026 reduction was Amylyx Pharmaceuticals, cutting an estimated $16.2M.
  • Great Point Partners fully exited Apogee Therapeutics in Q2 2026, selling an estimated $31.5M.
  • Great Point Partners's ten largest holdings make up 52% of its $529M portfolio in Q2 2026.
  • Great Point Partners opened 12 new positions and closed 12 in Q2 2026.
  • Great Point Partners's portfolio value rose 22% quarter-over-quarter to $529M.

Based on Great Point Partners's 13F filing for Q2 2026, filed 14 Aug 2026.